First Citizens Bank & Trust Co. decreased its stake in shares of Zoetis Inc (NYSE:ZTS) by 29.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 31,355 shares of the company’s stock after selling 12,898 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Zoetis were worth $3,156,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of ZTS. Berman Capital Advisors LLC acquired a new stake in shares of Zoetis during the 4th quarter valued at about $26,000. Athena Capital Advisors LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at about $29,000. TCI Wealth Advisors Inc. increased its stake in shares of Zoetis by 123.4% during the first quarter. TCI Wealth Advisors Inc. now owns 344 shares of the company’s stock worth $35,000 after acquiring an additional 190 shares during the period. Resources Investment Advisors Inc. acquired a new position in shares of Zoetis during the fourth quarter worth about $31,000. Finally, Lavaca Capital LLC acquired a new position in shares of Zoetis during the fourth quarter worth about $32,000. 91.07% of the stock is owned by institutional investors and hedge funds.
Several research analysts have weighed in on ZTS shares. Zacks Investment Research lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Sunday, January 6th. UBS Group began coverage on shares of Zoetis in a research note on Wednesday, January 23rd. They set a “neutral” rating and a $86.00 price target on the stock. BMO Capital Markets increased their price target on shares of Zoetis from $93.00 to $101.00 and gave the stock a “market perform” rating in a research note on Monday, February 25th. Stifel Nicolaus raised shares of Zoetis from a “hold” rating to a “buy” rating and raised their target price for the company from $97.00 to $110.00 in a research note on Monday, March 4th. Finally, SunTrust Banks started coverage on shares of Zoetis in a report on Tuesday, March 19th. They set a “hold” rating and a $100.00 price objective for the company. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Zoetis has an average rating of “Buy” and a consensus target price of $102.85.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.88 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.09. Zoetis had a net margin of 24.51% and a return on equity of 73.85%. The company had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.45 billion. During the same quarter in the previous year, the company posted $0.75 EPS. The business’s revenue was up 6.5% compared to the same quarter last year. As a group, research analysts forecast that Zoetis Inc will post 3.46 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, June 3rd. Shareholders of record on Thursday, April 18th will be paid a $0.164 dividend. This represents a $0.66 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend is Wednesday, April 17th. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.
In other news, EVP Clinton A. Jr. Lewis sold 6,124 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $101.60, for a total value of $622,198.40. Following the completion of the sale, the executive vice president now directly owns 54,484 shares in the company, valued at $5,535,574.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Roxanne Lagano sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $101.89, for a total transaction of $203,780.00. Following the transaction, the insider now directly owns 30,727 shares in the company, valued at approximately $3,130,774.03. The disclosure for this sale can be found here. Insiders sold 410,333 shares of company stock valued at $38,674,547 over the last quarter. Corporate insiders own 0.29% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: How analysts view the yield curve
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.